Get the Stockscreener App
16.11
2.26%
-0.235
After Hours:
16.02
-0.095
-0.59%
Avalo Therapeutics Inc stock is traded at $16.11, with a volume of 1.31M.
It is down -2.26% in the last 24 hours and up +14.80% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
See More
Previous Close:
$16.35
Open:
$16.57
24h Volume:
1.31M
Relative Volume:
0.95
Market Cap:
$842.63M
Revenue:
$59,000
Net Income/Loss:
$-78.26M
P/E Ratio:
-2.6434
EPS:
-6.0964
Net Cash Flow:
$-51.46M
1W Performance:
-1.78%
1M Performance:
+14.80%
6M Performance:
-13.85%
1Y Performance:
+326.13%
1-Day Range:
$15.90
$16.57
1-Week Range:
$15.90
$17.10
52-Week Range:
$3.4313
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
16.03 | 859.45M | 59,000 | -78.26M | -51.46M | -6.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Apr-06-26 | Initiated | Citizens | Mkt Outperform |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avalo Therapeutics (AVTX) CMO exercises options and sells 3,000 shares under plan - Stock Titan
Avalo Therapeutics (AVTX) price target increased by 18.49% to 47.94 - MSN
UBS Group AG Has $8.68 Million Stock Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty - TipRanks
Wolfe Research initiates coverage of Avalo Therapeutics (AVTX) with outperform recommendation - MSN
Logos Global (AVTX) discloses 1.675M-share position, 3.2% of stock - Stock Titan
Avalo Therapeutics stock soars after positive LOTUS trial results - MSN
RA Capital and principals report 9.99% stake in Avalo Therapeutics (AVTX) - Stock Titan
OrbiMed reports 475,165 Avalo Therapeutics shares (AVTX) at 2.1% - Stock Titan
BVF affiliates report ~2.35M AVTX shares (NYSE: AVTX) under group attribution - Stock Titan
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $55 - Moomoo
Caligan Partners and David Johnson report 7.2% stake in Avalo (AVTX) - Stock Titan
T. Rowe Price (AVTX) shows 2.16M shares, 9.5% of Avalo Therapeutics - Stock Titan
Avoro holds 1.41M shares in Avalo Therapeutics (NASDAQ: AVTX) - Stock Titan
These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results - Sahm
Apple To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
Avalo Therapeutics stock jumps 33% in pre-market session: Here's why - MSN
Wedbush Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $34 - Moomoo
AVTX Maintains by Citizens -- Price Target Lowered to $55.00 - GuruFocus
AVTX Maintained by Mizuho -- Price Target Raised to $45.00 - GuruFocus
Affinity Asset Advisors discloses 5.5% stake in Avalo Therapeutics (NASDAQ: AVTX) - Stock Titan
AVTX Maintained by Wedbush -- Price Target Lowered to $34.00 - GuruFocus
AVTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Mizuho Adjusts Price Target on Avalo Therapeutics to $45 From $39, Maintains Outperform Rating - Moomoo
Citizens Jmp Cuts Avalo Therapeutics (NASDAQ:AVTX) Price Target to $55.00 - MarketBeat
Wedbush Adjusts Price Target on Avalo Therapeutics to $34 From $40, Maintains Outperform Rating - Moomoo
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $58 - Moomoo
H.C. Wainwright cuts Avalo Therapeutics price target to $35 on trial data - Investing.com UK
Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $35.00 by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright cuts Avalo Therapeutics price target to $35 on trial data By Investing.com - Investing.com South Africa
Citizens cuts Avalo Therapeutics stock price target on equity financing - Investing.com UK
Citizens cuts Avalo Therapeutics stock price target on equity financing By Investing.com - Investing.com Australia
AVTX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.27, Implies 137% Upside - TradingView
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside - TradingView
Avalon (AVTX) Reports Promising Trial Results for Abdakibart in HS Treatment - GuruFocus
Avalo Therapeutics Q1 Net Loss Narrows - Moomoo
Avalo Therapeutics, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and SEC Filings Overview - Minichart
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Raised to $48.7, Implies 144% Upside - TradingView
Avalo Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Avalo Therapeutics Reports Positive Phase 2 Results for Abdakibart in Hidradenitis Suppurativa and Raises $431M to Fund Phase 3 Trial - Minichart
Is Avalo Therapeutics (AVTX) Overvalued After Q1 2026 EPS Beat? - GuruFocus
AVTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Flash (AVTX) Avalo Therapeutics Posts Q1 Loss $0.98 a Share, vs. FactSet Est of $1.03 Loss - marketscreener.com
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates - The Manila Times
Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary - TradingView
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):